Phase I trial of intravenous bispecific antibody (4G7XH22) in patients with refractory or relapsed non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL)
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bispecific monoclonal antibody 4G7xH22 (Primary) ; Sargramostim
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 03 May 2018 Biomarkers information updated
- 02 Aug 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 10 Sep 2005 New trial record.